Showing 1 - 16 results of 16 for search 'Giancarlo Bisagni', query time: 0.98s Refine Results
  1. 1
    Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search